References
- Brown B., Hall A. S. Renin–angiotensin system modulation; The weight of evidence. Am J Hypertens 2005; 18: 127S–133S
- The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 Guidelines for the management of arterial hypertension. Blood Press 2007; 16: 135–232
- Niskanen L., Hedner T., Hansson L., Lanke J., Niklason A., CAPPP Study Group. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first‐line therapy with an ACE inhibitor compared with a diuretic/beta‐blocker‐based treatment regimen: A subanalysis of the Captopril Prevention Project. Diabetes Care 2001; 24: 2091–2096
- Hansson L., Lindholm L. H., Niskanen L., Lanke J., Hedner T., Niklason A., et al. Effect of angiotensin‐converting‐enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611–616
- Niklason A., Hedner T., Niskanen L., Lanke J., Captopril Prevention ProjectStudy Group. Development of diabetes is retarded by ACE inhibition in hypertensive patients – a subanalysis of the Captopril Prevention Project (CAPPP). J Hypertens 2004; 22: 645–652
- Mancia G., Grassi G., Zanchetti A. New‐onset diabetes and antihypertensive drugs. J Hypertens 2006; 24: 3–10
- Julius S., Kjeldsen S. E., Weber M., Brunner H. R., Ekman S., Hansson L., , for the VALUE trial group, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine the VALUE randomised trial. Lancet 2004; 363: 2022–2031
- Arakawa S., Saku Y., Ibayashi S., Nagao T., Fujishima M. Blood pressure control and recurrence of hypertensive brain hemorrhage. Stroke 1998; 29: 1806–1809
- Svensson S., Kjellgren K. I., Ahlner J., Saljo R. Reasons for adherence with antihypertensive medication. Int J Cardiol 2000; 76: 157–163